查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1661058

医院获得性疾病检测市场报告（按适应症（UTI（泌尿道感染）、SSI（手术部位感染）、肺炎、血流感染、MRSA（耐甲氧西林金黄色葡萄球菌）等）和地区划分，2025 年至 2033 年

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球医院内疾病检测市场规模达到 140 亿美元。推动市场发展的因素有几个，包括老年人口的增加、医院内获得性感染（HAI）如泌尿道感染（UTI）、血液感染和肺炎的盛行率增加，以及接受各种外科手术的人数不断增加。

院内感染 (HAI) 或院内感染是在医院和医疗诊所内感染的疾病。院内感染是指在医院内发生的感染或疾病。即使在疗养院、復健中心、医院或任何其他临床环境附近，人们也可能感染此类疾病。大多数人在加护病房 (ICU) 和急诊室 (ER) 时感染医院感染。一般来说，这些疾病的潜伏期为患者入院后的48小时至4天。医院内感染疾病发生的一个主要原因是医院内部工作人员缺乏适当的卫生习惯。其他原因可能包括维护水准低于标准、医院工作人员的自满以及多重抗药性细菌 (MDRO) 的增加。一些最常见的院内感染包括肺炎、原发性血流感染、泌尿道感染等。当皮肤保护层接触到可能的威胁并导致感染时，尤其是在手术后，就会发生这种情况。

市场趋势：

在人口成长和医疗基础设施现代化的推动下，全球医疗设施的数量显着增加。这导致医院感染发生率上升，从而推动了医院内获得性疾病检测的需求。此外，随着技术的进步和科学创新，市场上已经有各种用于预防、诊断和监测医院感染的技术，例如微阵列、聚合酶链反应（PCR）、即时定位系统（RTLS）和固相杂交。 RTLS 等技术可以轻鬆防止医院感染在患者和工作人员中传播。患者对医院感染认识的不断增强，以及政府颁布法规对医院感染发病率高的医院进行惩罚，这些都是催化市场成长的其他因素。

本报告解答的关键问题

  • 2024 年全球医院内获得性疾病检测市场的市场规模是多少？ 2025 年至 2033 年全球医院内获得性疾病检测市场的成长如何？
  • 全球医院内获得性疾病检测市场的驱动因素有哪些？
  • 全球医院内获得性疾病检测市场的主要行业趋势是什么？
  • COVID-19 对全球医院内获得性疾病检测市场有何影响？
  • 全球医院内获得性疾病检测市场按适应症分類的情况如何？
  • 全球医院内获得性疾病检测市场的主要区域有哪些？
  • 全球医院内感染检测市场的关键公司/参与者有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球医院获得性疾病检测市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场区隔：按适应症
  • 市场分布：按地区
  • 市场预测
  • SWOT 分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价格分析

第六章：市场区隔：依适应症

  • UTI（泌尿道感染）
    • 市场趋势
    • 市场预测
  • SSI（手术部位感染）
    • 市场趋势
    • 市场预测
  • 肺炎
    • 市场趋势
    • 市场预测
  • 血流感染
    • 市场趋势
    • 市场预测
  • MRSA（抗甲氧西林金黄色葡萄球菌）
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第七章：市场区隔：依地区

  • 北美洲
    • 市场趋势
    • 市场预测
  • 欧洲
    • 市场趋势
    • 市场预测
  • 亚太地区
    • 市场趋势
    • 市场预测
  • 中东和非洲
    • 市场趋势
    • 市场预测
  • 拉丁美洲
    • 市场趋势
    • 市场预测

第 8 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • Cepheid, Inc.
Product Code: SR112025A1128

The global hospital acquired disease testing market size reached USD 14.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 49.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15% during 2025-2033. There are several factors that are driving the market, which include the rising geriatric population, increasing prevalence of hospital acquired infections (HAIs) like urinary tract infections (UTIs), bloodstream infections, and pneumonia, and the growing number of people undergoing different surgical procedures.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:

Breakup by Indication:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

  • The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
  • This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

  • 1.What is the market size for the global hospital acquired disease testing market 2024?
  • 2.What is the global hospital acquired disease testing market growth 2025-2033?
  • 3.What are the global hospital acquired disease testing market drivers?
  • 4.What are the key industry trends in the global hospital acquired disease testing market?
  • 5.What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6.What is the global hospital acquired disease testing market breakup by indication?
  • 7.What are the major regions in the global hospital acquired disease testing market?
  • 8.Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2024
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players